Published in Thromb J on December 08, 2014
Development of subcutaneous sustained release nanoparticles encapsulating low molecular weight heparin. J Adv Pharm Technol Res (2015) 0.76
Desmoid Fibromatosis Presenting as Deep Venous Thrombosis: A Case Report and Discussion. Am J Case Rep (2016) 0.75
Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report. J Med Case Rep (2016) 0.75
The Assessment of Thromboembolism Risk in Postbariatric Patient: Our Experience in 936 Patients. Plast Reconstr Surg Glob Open (2016) 0.75
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med (2011) 8.75
Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet (1960) 7.96
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
The epidemiology of venous thromboembolism. Circulation (2003) 6.97
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med (2007) 5.29
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Risk factors for venous thromboembolism. Circulation (2003) 4.64
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Natural history of venous thromboembolism. Circulation (2003) 3.67
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol (2008) 3.50
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Venous thromboembolism in the outpatient setting. Arch Intern Med (2007) 2.46
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med (2014) 2.37
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost (2011) 2.14
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol (2010) 1.98
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2012) 1.77
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood (2014) 1.61
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost (2010) 1.55
Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant (2005) 1.52
Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med (2008) 1.52
Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest (2001) 1.39
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis (2011) 1.30
Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke (2012) 1.25
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol (2011) 1.23
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2010) 1.12
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis (2011) 1.12
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke (2012) 1.10
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res (2011) 1.09
Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med (1987) 1.08
The post-thrombotic syndrome: progress and pitfalls. Br J Haematol (2006) 1.08
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost (2012) 1.06
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost (2013) 1.05
Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2009) 1.03
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med (2013) 0.96
New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs (2012) 0.93
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost (2005) 0.90
Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost (2012) 0.89
A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. J Thromb Haemost (2012) 0.88
Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban. Digestion (2014) 0.87
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiol Scand (2014) 0.86
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther (2014) 0.85
Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med (2011) 0.85
Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol (1992) 0.84
Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome. J Thromb Haemost (2013) 0.83
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost (2012) 0.81
Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol (2012) 0.80
Improving adherence to best-practice guidelines for venous thromboembolism risk assessment and prevention. Am J Health Syst Pharm (2011) 0.76